Evidence map›Paper›PMID 24763730›Full record

ArticlePloS one2014

Inhibition of breast cancer metastasis suppressor 1 promotes a mesenchymal phenotype in lung epithelial cells that express oncogenic K-RasV12 and loss of p53.

Emily H Hall, Yuan Liu, Aizhen Xiao, Lisa Shock, David L Brautigan, Marty W Mayo, Prasad S Adusumilli, David R Jones

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Emily H HallDepartment of Surgery, University of Virginia, Charlottesville, Virginia, United States of America.
Yuan LiuDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Aizhen XiaoDepartment of Surgery, University of Virginia, Charlottesville, Virginia, United States of America.
Lisa ShockDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, United States of America.
David L BrautiganDepartment of Microbiology, Immunology &Cancer Biology, and Center for Cell signaling, University of Virginia, Charlottesville, Virginia, United States of America.
Marty W MayoDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, United States of America.
Prasad S AdusumilliDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
David R JonesDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
University of Virginia · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Role of IKK in NSCLC: Modulation of SMRT and NF-kappaBR01CA104397 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI MAYO, MARTY W · 2004 to 2012
$2.4M
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1R01CA136705 · NCI · UNIVERSITY OF VIRGINIA · PI JONES, DAVID R · 2009 to 2013
$1.5M
Inflammatory Cytokines Link NF-kappaB with Bim Degradation and MetastasisR01CA132580 · NCI · UNIVERSITY OF VIRGINIA · PI MAYO, MARTY W · 2008 to 2012
$1.4M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA104397NCI NIH HHS R01 CA132580NCI NIH HHS R01 CA136705NCI NIH HHS T32 CA009109
6 · The paper itself

Abstract

Expression of the breast cancer metastasis suppressor 1 (BRMS1) protein is dramatically reduced in non-small cell lung cancer (NSCLC) cells and in primary human tumors. Although BRMS1 is a known suppressor of metastasis, the mechanisms through which BRMS1 functions to regulate cell migration and invasion in response to specific NSCLC driver mutations are poorly understood. To experimentally address this, we utilized immortalized human bronchial epithelial cells in which p53 was knocked down in the presence of oncogenic K-RasV12 (HBEC3-p53KD-K-RasV12). These genetic alterations are commonly found in NSCLC and are associated with a poor prognosis. To determine the importance of BRMS1 for cytoskeletal function, cell migration and invasion in our model system we stably knocked down BRMS1. Here, we report that loss of BRMS1 in HBEC3-p53KD-K-RasV12 cells results in a dramatic increase in cell migration and invasion compared to controls that expressed BRMS1. Moreover, the loss of BRMS1 resulted in additional morphological changes including F-actin re-distribution, paxillin accumulation at the leading edge of the lamellapodium, and cellular shape changes resembling mesenchymal phenotypes. Importantly, re-expression of BRMS1 restores, in part, cell migration and invasion; however it does not fully reestablish the epithelial phenotype. These finding suggests that loss of BRMS1 results in a permanent, largely irreversible, mesenchymal phenotype associated with increased cell migration and invasion. Collectively, in NSCLC cells without p53 and expression of oncogenic K-Ras our study identifies BRMS1 as a key regulator required to maintain a cellular morphology and cytoskeletal architecture consistent with an epithelial phenotype.

Indexed as

Actin CytoskeletonAlveolar Epithelial CellsAnimalsCarcinogenesisCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionGene Knockdown TechniquesHumansMice, NudeMutationNeoplasm ProteinsPaxillinPhenotypeProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)BRMS1 protein, humanKRAS protein, humanNeoplasm ProteinsPaxillinProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)PXN protein, humanras ProteinsRepressor ProteinsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID24763730
PMCPMC3999110
OpenAlexW2001171563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.